|Targets||Isocitrate Dehydrogenase (IDH)|
Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2).
Ivosidenib, also called AG-120, is an oral inhibitor that specifically inhibits a mutated form of IDH1 in the cytoplasm.
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
Mutant IDH1-IN-2, aslo called as SCHEMBL14831158, is an inhibitor of mutant IDH protein. It is developed for the treatment of diseases associated with such muta...
Mutant IDH1-IN-1, a mutant IDH1 R132H inhibitor, could be used in some biological studies.
GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50= 4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 st...
SCHEMBL14831541, also called as Mutant IDH1 inhibitor, is an inhibitor of mutant IDH1 which is key enzymes found in cellular metabolism.